Characteristics and Survival Outcomes of Children With Hodgkin Lymphoma Treated Primarily With Chemotherapy
| Autor: | Fozia Naz, Muhammad Shamvil Ashraf, Mohammad Yawar Yakoob |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Vincristine Cyclophosphamide Adolescent Dacarbazine medicine.medical_treatment 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Child Survival rate Retrospective Studies Chemotherapy business.industry Infant Newborn Infant Retrospective cohort study Hematology Prognosis Hodgkin Disease Survival Rate Oncology ABVD 030220 oncology & carcinogenesis Child Preschool Pediatrics Perinatology and Child Health Prednisolone Female business 030215 immunology medicine.drug Follow-Up Studies |
| Zdroj: | Journal of pediatric hematology/oncology. 41(6) |
| ISSN: | 1536-3678 |
| Popis: | Background Hodgkin disease is a malignant tumor of the lymphatic system that comprises ∼6% of childhood cancers. In developing countries, efforts are made to ensure adherence to standard protocol/regimens, study patients' outcomes, and compare with that in developed world. Materials and methods We conducted a retrospective medical records' review of 212 children younger than 20 years presenting to The Indus Hospital in Pakistan with previously untreated Hodgkin lymphoma between August 2000 and December 2012. We collected demographic and other epidemiologic variables such as age, sex, stage, subtype of disease, and survival outcomes. Results The mean±SD age of patients at time of diagnosis was 9.0±3.8 years with a male to female ratio of ∼4.7:1. In total, 44 (20.8%) patients were 5 years of age or above at presentation. Overall, 131 (61.8%) patients presented with B-symptoms and mixed cellularity was the most frequently diagnosed subtype in 65.1% of cases. In total, 170 (80.2%) achieved full remission after completion of chemotherapy. Patients were treated with alternating cycles of ABVD (Adriamycin, Bleomycin, Vincristine, and Dacarbazine) and COPDAC (Cyclophosphamide, Vincristine, Prednisolone, and Dacarbazine). The majority (n=114, 59.1%) received 6 cycles of chemotherapy, 44 (22.8%) received ≤4 cycles followed by 24 (12.4%) receiving 8 cycles. Radiotherapy was administered only to those patients with significant residual disease at the end of chemotherapy (n=20, 10%). The 5-year overall survival and event-free survival in our cohort was 89.6% and 82.1%, respectively. Conclusion Our findings suggest that treatment with 4 to 8 alternating cycles of ABVD/COPDAC has an excellent outcome in childhood Hodgkin disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|